Vaccines

Moderna and Merck Personalized mRNA Vaccine Cuts Melanoma Recurrence in Phase 3 Readout

Companies reported interim topline results showing large reductions in recurrence and distant metastasis with full datasets, safety tables and regulatory review still pending.